Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro is a clinical stage drug developer in Atlanta working on treatments for Alzheimer's and other brain disorders. It last closed at $1.13 on Nov 17, down 4.24% on the day. ALZN reports earnings on Tue, Dec 8, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From ALZN's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 19 | Ascendiant Capital | Maintained | Buy | $26 |
Technical Analysis
The stock is 13% below its 20 day and 30% below its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $1.10, and the nearest resistance the Pivot at $1.14.
| RSI (14) | 35.18 | Weak, oversold below 30 | Neutral |
| MACD | -0.04 | Below its signal line | Bearish |
| Stochastic | 13.3 | Near the bottom of its range | Oversold |
| ADX (14) | 27.2 | Trending down | |
| Williams %R | -96.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -95.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −22.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.13 | Typical daily range, 11.9% of price |
| RSI (14) | 40.19 | Middle of its range | Neutral |
| MACD | -0.09 | Below its signal line | Bearish |
| Stochastic | 18.8 | Near the bottom of its range | Oversold |
| ADX (14) | 13.7 | No clear trend | |
| Williams %R | -96.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -96.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −34.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.27 | Typical daily range, 24.0% of price |
What happened before
See how ALZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ALZN in the last 90 days.
ALZN Institutional Ownership
Full report →- ▲7 buying vs 3 selling
- ▼Held by funds -0.6 pts
- ▲Funds holding +4
- ▲Superinvestors: 1 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 15 | 11 | +36.4% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 28.2% | 28.8% | −0.6 pts |
| New / increased | 4 / 3 | 1 / 2 | +133.3% |
| Reduced / sold out | 3 / 0 | 4 / 3 | −57.1% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALZN is in one of them and how their past ALZN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALZN in an article yet. Here's the latest on the wider market.
About Alzamend Neuro
Alzamend Neuro is a clinical stage drug developer based in Atlanta, Georgia, focused on brain disorders. It is working on treatments for Alzheimer's disease, bipolar disorder, major depressive disorder and post traumatic stress disorder. Its lead candidate, AL001, is a form of lithium designed to treat these conditions, and it is in human clinical trials. Its target patients are people living with these illnesses.
- Headquarters
- Atlanta, GA
